Baxdela

Baxdela Uses, Dosage, Side Effects, Food Interaction and all others data.

Baxdela is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.

Baxdela is a fluoroquinolone antibacterial drug which kills bacterial cells .

Baxdela
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Baxdela
Availability	Prescription only
Generic	Delafloxacin
Delafloxacin Other Names	Delafloxacin
Related Drugs	amoxicillin, doxycycline, ciprofloxacin, metronidazole, azithromycin, clindamycin, ceftriaxone, Augmentin, amoxicillin / clavulanate, cefdinir
Weight	300mg, 450mg,
Type	Intravenous, Intravenous Powder For Injection, Oral Tablet, Oral/injection
Formula	C₁₈H₁₂ClF₃N₄O₄
Weight	Average: 440.76 Monoisotopic: 440.0499171
Protein binding	Delafloxacin is 84% bound to human plasma proteins . It primarily binds to serum albumin.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Baxdela is a fluoroquinolone antibiotic used to treat skin and skin structure infections.

Baxdela is indicated for the treatment of acute bacterial skin and skin structure infections caused by the Gram-positive organisms Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis as well as the Gram-negative organisms Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa .

How Baxdela works

Baxdela inhibits the activity of bacterial DNA topoisomerase IV and DNA gyrase (topoisomerase II) . This interferes with bacterial DNA replication by preventing the relaxation of positive supercoils introduced as part of the elongation process . The resultant strain inhibits further elongation. Baxdela exerts concentration-dependent bacteriocidal activity .

Toxicity

The most common adverse reactions noted with Baxdela were nausea (8%), diarrhea (8%), headache (3%), transaminase elevations (3%), and vomiting (2%) . Fluoroquinolones are associated with increased frequency of tendon rupture and tendonitis, increased risk of peipheral neuropathy, excacerbation of myasthenia gravis, and development of Clostridium difficile-associated diarrhea. Fluoroquinolones are also associated with an increased risk of central nervous system reactions (CNS), including: convulsions and increased intracranial pressure (including pseudotumor cerebri) and toxic psychosis. Fluoroquinolones may also cause CNS reactions of nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or acts.

Food Interaction

Avoid multivalent ions. Separate the administration of multivalent cations from delafloxacin by at least 6 hours before or 2 hours after delafloxacin.
Take separate from antacids. The administration of antacids should be separated from delafloxacin by at least 6 hours before or 2 hours after delafloxacin.
Take with or without food.

Baxdela multivitamins interaction

[Moderate] ADJUST DOSING INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.

Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.

The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.

The bioavailability of ciprofloxacin has been reported to decrease by as much as 90% when administered with antacids containing aluminum or magnesium hydroxide.

When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.

When coadministered with Suprep Bowel Prep (magnesium

Please consult individual product labeling for specific recommendations.

Baxdela Disease Interaction

Major: colitis, renal impairment, CNS disorders, myasthenia gravis, peripheral neuropathy, tendonitisModerate: aortic aneurysm, crystalluria, diabetes

Volume of Distribution

The steady sate volume of distrubution of Baxdela is 30-48 liters .

Elimination Route

The median time to peak plasma concentration for orally administered Baxdela is 0.75 (0.5-4.0) hours after a single dose and 1.00 (0.5-6.0) hours for steady state dosing . The median time to peak plasma concentration for intravenously administered Baxdela is 1.00 (1.0-1.2) hours for a single dose and 1.0 (1.0-1.0) hour for steady state dosing. The absolute bioavailability for orally administed Baxdela is 58.8%.

Half Life

The mean half life of elimination of Baxdela is 3.7 hours after a single intravenous administration . The mean half life of elimination for multple oral administrations is 4.2-8.5 hours.

Clearance

The mean total clearance of Baxdela is 16.3 liters per hour . Renal clearance accounts for 35-45% of total clearance.

Elimination Route

After a single intravenous dose, 65% of Baxdela was excreted in the urine either unchanged or as glucuronide metabolites with 28% excreted unchanged in the feces . After a single oral dose, 50% of Baxdela was excreted in the urine either unchanged or as glucuronide metabolites with 48% excreted unchanged in the feces.